Profil
Charlotta Gauffin is currently Chief Scientific Officer at Dicot Pharma AB since 2022.
Former positions include Head-Clinical Trial Management at LIDDS AB from 2019 to 2022, and Manager-Clinical Project & Program Director at Medivir AB, Biovitrum AB, and Galderma Holding AB. Education includes graduate and doctorate degrees from the University of Uppsala.
Postes actifs de Charlotta Gauffin
| Sociétés | Poste | Début |
|---|---|---|
| DICOT PHARMA AB | Directeur Technique/Scientifique/R&D | 11/07/2022 |
Anciens postes connus de Charlotta Gauffin
| Sociétés | Poste | Fin |
|---|---|---|
| LIDDS AB | Directeur Technique/Scientifique/R&D | 01/07/2022 |
Galderma Holding AB | Directeur Technique/Scientifique/R&D | - |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Develops pharmaceuticals and conducts medical research services | Directeur Technique/Scientifique/R&D | - |
| MEDIVIR AB | Directeur Technique/Scientifique/R&D | - |
Formation de Charlotta Gauffin
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Medivir AB
Medivir AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Develops pharmaceuticals and conducts medical research services | Commercial Services |
University of Uppsala
University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LIDDS AB
LIDDS AB Pharmaceuticals: MajorHealth Technology Focuses on the development of treatment alternatives and hormonal therapy for prostate cancer | Health Technology |
Galderma Holding AB | |
Dicot Pharma AB
Dicot Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs to treat erectile failure | Health Technology |
















